Quick Answer
BioAge Labs, Inc. reported R&D Expense of $73.97 million for fiscal year 2025.
BioAge Labs, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $73.97M | +25.3% |
| 2024 | $59.04M | +74.2% |
| 2023 | $33.89M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.51M | -7.5% | -6.7% |
| June 30, 2025 | $19.84M | +89.5% | +78.6% |
| March 31, 2025 | $11.11M | +19.2% | -44.5% |
| September 30, 2024 | $20.02M | +206.5% | +91.2% |
| June 30, 2024 | $10.47M | — | +12.3% |
| March 31, 2024 | $9.32M | — | +42.7% |
| September 30, 2023 | $6.53M | — | — |
- BioAge Labs, Inc. showed an increase of +25.3% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, BioAge Labs, Inc.’s r&d expense has grown by 118.3% (from $33.89 million to $73.97 million).
- The most recent figure is from BioAge Labs, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: